A Pivotal Clinical Study to Investigate the Safety and Efficacy of Efimosfermin Compared With Placebo in Adult Participants With Compensated Cirrhosis Due to Metabolic Dysfunction-associated Steatohepatitis (MASH)
NCT07701993
This study is recruiting at 13 US sites in 5 states, according to its ClinicalTrials.gov record last updated .
Summary
This study will investigate the safety and efficacy of efimosfermin alfa in participants with compensated cirrhosis due to MASH.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Metabolic Dysfunction-associated Steatohepatitis
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 3
- Ages
- 18 to 75 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- GlaxoSmithKline
- Last updated on ClinicalTrials.gov
- September 30, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Arkansas · 1
- GSK Investigational Site · Little Rock, AR
California · 1
- GSK Investigational Site · Folsom, CA
Florida · 3
- GSK Investigational Site · Miami, FL
- GSK Investigational Site · Miami, FL
- GSK Investigational Site · Ocala, FL
Missouri · 1
- GSK Investigational Site · St Louis, MO
Texas · 7
- GSK Investigational Site · Arlington, TX
- GSK Investigational Site · Austin, TX
- GSK Investigational Site · Bellaire, TX
- GSK Investigational Site · Dallas, TX
- GSK Investigational Site · Humble, TX
- GSK Investigational Site · San Antonio, TX
- GSK Investigational Site · San Antonio, TX
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.